Nomenclature of HBV core protein-targeting antivirals

Affiliations

• ¹ Hepatology Department, INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France. fabien.zoulim@inserm.fr.
• ² Molecular and Cellular Biochemistry Department, Indiana University, Bloomington, IN, USA.
• ³ Federal Institute for Drugs and Medical Devices, BfArM, Bonn, Germany.
• ⁴ US Food and Drug Administration, Silver Spring, MD, USA.
• ⁵ Aligos Therapeutics, San Francisco, CA, USA.
• ⁶ Arrive Bio, San Francisco, CA, USA.
• ⁷ Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
• ⁸ Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• ⁹ Department of Clinical Microbiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.
• ¹⁰ Janssen Pharmaceutica NV, Beerse, Belgium.
• ¹¹ Aerium Therapeutics, Boston, MA, USA.
• ¹² Arbutus Biopharma Inc., Department of Biology, Warminster, PA, USA.
• ¹³ Department of Medicine II, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
• ¹⁴ Assembly Biosciences, South San Francisco, CA, USA.
• ¹⁵ Cooperman Barnabas Medical Center, RWJBarnabas-Rutgers Medical Group, Livingston, NJ, USA.
• ¹⁶ Swedish Medical Products Agency, Uppsala University, Uppsala, Sweden.
• ¹⁷ The Forum for Collaborative Research, Washington, DC, USA.
• ¹⁸ Department of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, Netherlands.
• ¹⁹ Toronto Centre for Liver Disease, University of Toronto, Ontario, Canada.